Beyond Newsroom

Biogen's Strategic Shift: Felzartamab's Promise in IgAN and Beyond Fuels Buy Rating

TipRanksOct 28 20:28

BTIG Maintains Beyond(BYON.US) With Hold Rating

Futu NewsOct 27 00:32

Maxim Group Maintains Beyond(BYON.US) With Buy Rating

Futu NewsOct 26 20:32

Tom Forte Maintains Buy Rating on Beyond Despite Weak Q3 Results, Citing Strategic Vision and Financial Resilience

TipRanksOct 26 19:47

Beyond Is Maintained at Buy by Maxim Group

Dow JonesOct 26 02:29

Maxim Group Maintains Buy on Beyond, Lowers Price Target to $26

BenzingaOct 26 02:20

Beyond Price Target Cut to $8.00/Share From $14.00 by Piper Sandler

Dow JonesOct 25 22:50

Wedbush Maintains Beyond(BYON.US) With Buy Rating, Cuts Target Price to $15

Futu NewsOct 25 21:33

A Quick Look at Today's Ratings for Beyond(BYON.US), With a Forecast Between $6 to $14

Futu NewsOct 25 21:10

Piper Sandler Remains a Hold on Beyond Inc (BYON)

TipRanksOct 25 19:42

Beyond Is Maintained at Buy by Needham

Dow JonesOct 25 17:59

Needham Maintains Buy on Beyond, Lowers Price Target to $9

BenzingaOct 25 17:49

Beyond Analyst Ratings

BenzingaOct 25 17:48

Needham Initiates Beyond(BYON.US) With Buy Rating, Announces Target Price $13

Futu NewsOct 23 19:35

Beyond Price Target Announced at $13.00/Share by Needham

Dow JonesOct 23 19:11

Needham Upgrades Beyond to Buy From Hold, Price Target Is $13

MT NewswiresOct 23 19:10

Beyond Analyst Ratings

BenzingaOct 23 19:04

Wedbush Maintains Beyond(BYON.US) With Buy Rating, Maintains Target Price $25

Futu NewsOct 19 00:31

Beyond Inc's Strategic Growth Potential and Multi-Brand Strategy Drive Buy Rating

TipRanksOct 18 23:40

Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold

TipRanksOct 15 23:49